Target Validation to Biomarker Development

Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 2004; 3(8): 711–5 Same old story? Nat Rev Drug Discov 2007; 6 (2): 97 Collins I, Workman P. New approaches to molecular cancer therapeutics. Nat Chem Biol 2006; 2(12): 689–700 Benson JD, Chen YN, Cornell-Kennon SA, et al. Validating cancer drug targets. Nature 2006; 441(7092): 451–6 Sawyers CL. Opportunities and challenges in the development of kinase inhibitor therapy for cancer. Genes Dev 2003; 17(24): 2998–3010 Sanger Institute. Cancer gene census [online]. Available from URL: http://www.sanger.ac.uk/genetics/CGP/Census/ [Accessed 2008 Feb 25] Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417(6892): 949–54 Garraway LA, Widlund HR, Rubin MA, et al. Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 2005; 436(7047): 117–22 Kim H, Muller WJ. The role of the epidermal growth factor receptor family in mammary tumorigenesis and metastasis. Exp Cell Res 1999; 253(1): 78–87 Kitayama H, Tsujimura T, Matsumura I, et al. Neoplastic transformation of normal hematopoietic cells by constitutively activating mutations of c-kit receptor tyrosine kinase. Blood 1996; 88(3): 995–1004 Li QX, Tan P, Ke N, et al. Ribozyme technology for cancer gene target identification and validation. Adv Cancer Res 2007; 96: 103–43 Kurreck J. Antisense technologies: improvement through novel chemical modifications. Eur J Biochem 2003; 270(8): 1628–44 Pendergrast PS, Marsh HN, Grate D, et al. Nucleic acid aptamers for target validation and therapeutic applications. J Biomol Tech 2005; 16(3): 224–34 Bennett CF. Efficiency of antisense oligonucleotide drug discovery. Antisense Nucleic Acid Drug Dev 2002; 12(3): 215–24 Scherer LJ, Rossi JJ. Approaches for the sequence-specific knockdown of mRNA. Nat Biotechnol 2003; 21(12): 1457–65 Napoli C, Lemieux C, Jorgensen R. Introduction of a Chimeric chalcone synthase gene into petunia results in reversible co-suppression of homologous genes in trans. Plant Cell 1990; 2(4): 279–89 Cerutti H, Casas-Mollano JA. On the origin and functions of RNA-mediated silencing: from protists to man. Curr Genet 2006; 50(2): 81–99 Fire A, Xu S, Montgomery MK, et al. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998; 391(6669): 806–11 Kavi HH, Fernandez HR, Xie W, et al. RNA silencing in Drosophila. FEBS Lett 2005; 579: 5940–9 Qi Y, Hannon GJ. Uncovering RNAi mechanisms in plants: biochemistry enters the foray. FEBS Lett 2005; 579: 5899–903 Elbashir SM, Harborth J, Lendeckel W, et al. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001; 411(6836): 494–8 Kim DH, Rossi JJ. Strategies for silencing human disease using RNA interference. Nat Rev Genet 2007; 8(3): 173–84 Bernstein E, Caudy AA, Hammond SM, et al. Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature 2001; 409(6818): 363–6 Amarzguioui M, Rossi JJ, Kim D. Approaches for chemically synthesized siRNA and vector-mediated RNAi. FEBS Lett 2005; 579(26): 5974–81 Berezikov E, Guryev V, van de BJ, et al. Phylogenetic shadowing and computational identification of human microRNA genes. Cell 2005; 120(1): 21–4 Bartel DP, Chen CZ. Micromanagers of gene expression: the potentially widespread influence of metazoan microRNAs. Nat Rev Genet 2004; 5(5): 396–400 Esquela-Kerscher A, Slack FJ. Oncomirs: microRNAs with a role in cancer. Nat Rev Cancer 2006; 6(4): 259–69 Wienholds E, Plasterk RH. MicroRNA function in animal development. FEBS Lett 2005; 579(26): 5911–22 Ui-Tei K, Naito Y, Takahashi F, et al. Guidelines for the selection of highly effective siRNA sequences for mammalian and chick RNA interference. Nucleic Acids Res 2004; 32(3): 936–48 Kim DH, Behlke MA, Rose SD, et al. Synthetic dsRNA dicer substrates enhance RNAi potency and efficacy. Nat Biotechnol 2005; 23(2): 222–6 Sledz CA, Holko M, de Veer MJ, et al. Activation of the interferon system by short-interfering RNAs. Nat Cell Biol 2003; 5(9): 834–9 de Fougerolles A, Vornlocher HP, Maraganore J, et al. Interfering with disease: a progress report on siRNA-based therapeutics. Nat Rev Drug Discov 2007; 6(6): 443–53 McCaffrey AP, Meuse L, Pham TT, et al. RNA interference in adult mice. Nature 2002; 418(6893): 38–9 Soutschek J, Akinc A, Bramlage B, et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 2004; 432: 173–8 Grimm D, Kay MA. Therapeutic application of RNAi: is mRNA targeting finally ready for prime time?J Clin Invest 2007; 117: 3633–41 Zimmermann TS, Lee AC, Akinc A, et al. RNAi-mediated gene silencing in non-human primates. Nature 2006; 441(7089): 111–4 Doench JG, Petersen CP, Sharp PA. siRNAs can function as miRNAs. Genes Dev 2003; 17(4): 438–42 Jackson AL, Burchard J, Schelter J, et al. Widespread siRNA “off-target” transcript silencing mediated by seed region sequence complementarity. RNA 2006; 12(7): 1179–87 Jackson AL, Burchard J, Leake D, et al. Position-specific chemical modification of siRNAs reduces “off-target” transcript silencing. RNA 2006; 12(7): 1197–205 Mook OR, Baas F, de Wissel MB, et al. Evaluation of locked nucleic acid-modified small interfering RNA in vitro and in vivo. Mol Cancer Ther 2007; 6(3): 833–43 Iorns E, Lord CJ, Turner N, et al. Utilizing RNA interference to enhance cancer drug discovery. Nat Rev Drug Discov 2007; 6(7): 556–68 Berns K, Hijmans EM, Mullenders J, et al. A large-scale RNAi screen in human cells identifies new components of the p53 pathway. Nature 2004; 428(6981): 431–7 Kittler R, Pelletier L, Heninger AK, et al. Genome-scale RNAi profiling of cell division in human tissue culture cells. Nat Cell Biol 2007; 9(12): 1401–12 Moffat J, Grueneberg DA, Yang X, et al. A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen. Cell 2006; 124(6): 1283–98 MacKeigan JP, Murphy LO, Blenis J. Sensitized RNAi screen of human kinases and phosphatases identifies new regulators of apoptosis and chemoresistance. Nat Cell Biol 2005; 7(6): 591–600 Krausz E. High-content siRNA screening. Mol Biosyst 2007; 3(4): 232–40 Neumann B, Held M, Liebel U, et al. High-throughput RNAi screening by time-lapse imaging of live human cells. Nat Methods 2006; 3(5): 385–90 Zheng L, Liu J, Batalov S, et al. An approach to genomewide screens of expressed small interfering RNAs in mammalian cells. Proc Natl Acad Sci USA 2004; 101(1): 135–40 Brummelkamp TR, Fabius AW, Mullenders J, et al. An shRNA barcode screen provides insight into cancer cell vulnerability to MDM2 inhibitors. Nat Chem Biol 2006; 2(4): 202–6 Draviam VM, Stegmeier F, Nalepa G, et al. A functional genomic screen identifies a role for TAO1 kinase in spindle-checkpoint signalling. Nat Cell Biol 2007; 9(5): 556–64 Ngo VN, Davis RE, Lamy L, et al. A loss-of-function RNA interference screen for molecular targets in cancer. Nature 2006; 441(7089): 106–10 Sarthy AV, Morgan-Lappe SE, Zakula D, et al. Survivin depletion preferentially reduces the survival of activated K-Ras-transformed cells. Mol Cancer Ther 2007; 6(1): 269–76 Rottmann S, Wang Y, Nasoff M, et al. A TRAIL receptor-dependent synthetic lethal relationship between MYC activation and GSK3beta/FBW7 loss of function. Proc Natl Acad Sci U S A 2005; 102(42): 15195–200 Collins CS, Hong J, Sapinoso L, et al. A small interfering RNA screen for modulators of tumor cell motility identifies MAP4K4 as a promigratory kinase. Proc Natl Acad Sci U S A 2006; 103(10): 3775–80 Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005; 434(7035): 917–21 Gartel AL, Kandel ES. RNA interference in cancer. Biomol Eng 2006; 23(1): 17–34 Wacheck V, Losert D, Gunsberg P, et al. Small interfering RNA targeting bcl-2 sensitizes malignant melanoma. Oligonucleotides 2003; 13(5): 393–400 Spankuch-Schmitt B, Bereiter-Hahn J, Kaufmann M, et al. Effect of RNA silencing of polo-like kinase-1 (PLK1) on apoptosis and spindle formation in human cancer cells. J Natl Cancer Inst 2002; 94(24): 1863–77 Choudhury A, Charo J, Parapuram SK, et al. Small interfering RNA (siRNA) inhibits the expression of the Her2/neu gene, upregulates HLA class I and induces apoptosis of Her2/neu positive tumor cell lines. Int J Cancer 2004; 108(1): 71–7 Brummelkamp TR, Bernards R, Agami R. Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell 2002; 2(3): 243–7 Lage H. Potential applications of RNA interference technology in the treatment of cancer. Future Oncol 2005; 1(1): 103–13 Williams NS, Gaynor RB, Scoggin S, et al. Identification and validation of genes involved in the pathogenesis of colorectal cancer using cDNA microarrays and RNA interference. Clin Cancer Res 2003; 9(3): 931–46 Hoeflich KP, Gray DC, Eby MT, et al. Oncogenic BRAF is required for tumor growth and maintenance in melanoma models. Cancer Res 2006; 66(2): 999–1006 Pan Q, Bao LW, Kleer CG, et al. Protein kinase C epsilon is a predictive biomarker of aggressive breast cancer and a validated target for RNA interference anti-cancer therapy. Cancer Res 2005; 65(18): 8366–71 Bae KM, Wang H, Jiang G, et al. Protein kinase C epsilon is overexpressed in primary human non-small cell lung cancers and functionally required for proliferation of non-small cell lung cancer cells in a p21/Cip1-dependent manner. Cancer Res 2007; 67(13): 6053–63 Pan Q, Bao LW, Teknos TN, et al. Targeted disruption of protein kinase C epsilon reduces cell invasion and motility through inactivation of RhoA and RhoC GTPases in head and neck squamous cell carcinoma. Cancer Res 2006; 66(19): 9379–84 Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001; 69: 89–95 Frank R, Hargreaves R. Clinical biomarkers in drug discovery and development. Nat Rev Drug Discov 2003; 2(7): 566–80 Ackermann BL, Hale JE, Duffin KL. The role of mass spectrometry in biomarker discovery and measurement. Curr Drug Metab 2006; 7(5): 525–39 Ayers M, Fargnoli J, Lewin A, et al. Discovery and validation of biomarkers that respond to treatment with brivanib alaninate, a small-molecule VEGFR-2/ FGFR-1 antagonist. Cancer Res 2007; 67(14): 6899–906 Kovar H. Context matters: the hen or egg problem in Ewing’s sarcoma. Semin Cancer Biol 2005; 15(3): 189–96 Stegmaier K, Wong JS, Ross KN, et al. Signature-based small molecule screening identifies cytosine arabinoside as an EWS/FLI modulator in Ewing sarcoma. PLoS Med 2007; 4(4): e122 Nobelprize.org. The Nobel Prize in physiology or medicine [online]. Available from URL: http://nobelprize.org/nobel_prizes/medicine/laureates/2006/ [Accessed 2008 Feb 25]